BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15377438)

  • 1. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 4. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
    Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N
    Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 10. [Arsenic trioxide as a therapeutic agent in APL].
    Emi N
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
    [No Abstract]   [Full Text] [Related]  

  • 11. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 14. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 17. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    Ducas RA; Seftel MD; Ducas J; Seifer C
    J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenicals in hematologic cancers.
    Novick SC; Warrell RP
    Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.